Home
Contact Us

Member Profile
Go Back

Name:
Dr. Jennifer K Richer, PhD
Title:
Professor
Company:
University of Colorado Anschutz Medical Campus
Membership:
Full 
Bio:
Dr. Jennifer Richer, Professor with tenure, Department of Pathology, University of Colorado Anschutz Medical Campus, has studied steroid hormone receptor action in breast for over 25 years. Translational studies from her lab led to two completed clinical trials targeting the androgen receptor in primary and metastatic breast cancer. The Richer lab also discovered a mechanism by which carcinomas co-opt use of immune-suppressive factors typically made by trophoblasts to ensure fetal tolerance during pregnancy. Dr. Richer has worked extensively with patient advocates on Department of Defense Breast Cancer Research Program Clinical Translational and Clinical Expansion Awards. Dr. Richer is passionate about supporting the next generation of scientists and has served as principal investigator of the University of Colorado’s American Cancer Society Institutional Research Grant for junior faculty and the Diversity in Cancer Research Summer Fellowship Program. She received the Dean’s Mentoring Award and NIH Broadening Experiences in Scientific Training (BEST) Faculty Sponsor Award in 2015. Trainees in her laboratory have obtained numerous fellowships including NIH F31, F32, F99/K00, and K99/R00 grants, and other career development awards from federal and private foundations. Richer served 5 years as co-leader of the University of Colorado Cancer Center Tumor Host Interactions Program and her national service includes 5 years as a standing member of the NIH NCI Tumor Cell Biology study section and many years of service on numerous additional grant review panels. She was the Basic Science Chair for The Endocrine Society Annual Meeting 2021 and Co-chair of the 2016 Keystone Symposium on Nuclear Hormone Receptors. She is associate editor for Endocrinology and Breast Cancer Research. Dr. Richer was named as Graduate School Dean at the University of Colorado Anschutz Medical Campus in February 2023, a half time position so that she can continue to lead her active breast cancer research program.